[
  {
    "ts": null,
    "headline": "Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?",
    "summary": "CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.",
    "url": "https://finnhub.io/api/news?id=971e42183b0a3ae954f53d433b958604452fd640f7e5d38af7326af6f71e751e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756477320,
      "headline": "Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?",
      "id": 136573092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.",
      "url": "https://finnhub.io/api/news?id=971e42183b0a3ae954f53d433b958604452fd640f7e5d38af7326af6f71e751e"
    }
  }
]